JP5737825B2 - リファキシミンの新規多形、その製造方法、及び医薬製剤中でのその使用 - Google Patents
リファキシミンの新規多形、その製造方法、及び医薬製剤中でのその使用 Download PDFInfo
- Publication number
- JP5737825B2 JP5737825B2 JP2007557398A JP2007557398A JP5737825B2 JP 5737825 B2 JP5737825 B2 JP 5737825B2 JP 2007557398 A JP2007557398 A JP 2007557398A JP 2007557398 A JP2007557398 A JP 2007557398A JP 5737825 B2 JP5737825 B2 JP 5737825B2
- Authority
- JP
- Japan
- Prior art keywords
- rifaximin
- crystal
- water
- ethyl alcohol
- water content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
- C07D499/48—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical
- C07D499/58—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical
- C07D499/64—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Description
リファキシミン(INN;メルクインデックス,XIII版,8304を参照)は、リファマイシンクラスに属する抗生物質であって、まさに、これは伊国特許IT1154655号に説明され請求項に記載されているピリド−イミダゾ・リファマイシンである。一方、欧州特許EP0161534号には、リファマイシンO(メルクインデックス,XIII版,8301)から出発してそれを製造するための方法が説明され請求項に記載されている。
既述のように、本発明の対象は、リファキシミン(INN)として知られている抗生物質のδ形とε形、その製造方法、および経口または局所用の医薬製剤の製造におけるそれらの使用である。
用いた放射線:K(α1)、K(α2)
発電機の電圧および電流:KV40,mA40
モノクロメーター:グラファイト
ステップサイズ:0.02
ステップ当たりの時間:1.25秒
出発および最終角2θ値:3.0°÷30.0°
分析サンプル中に存在する水含量の評価は、常に、Karl Fisher法で行った。
(粗リファキシミンおよび乾燥粗リファキシミンの調製)
メカニカルスターラー、温度計および還流冷却器を備える三つ口フラスコに、室温で、脱塩水120ml、エチルアルコール96ml、リファマイシンO63.5gおよび2−アミノ−4−メチルピリジン27.2gを順次仕込む。仕込んだ後、その物(mass)を47±3℃で加熱し、この温度で5時間攪拌を続け、次に、20±3℃まで冷却し、脱塩水9ml、エチルアルコール12.6ml、アスコルビン酸1.68gおよび濃塩酸9.28gからなる別途調製された混合物を、30分間で加える。添加終了時、その物を20±3℃の内部温度で30分間攪拌を続け、次に、同じ温度で、濃塩酸7.72gをpHが2.0になるまで滴下する。
(リファキシミンεの調製)
実施例1を繰り返してδ形を得た後、固体粉末をさらに減圧下に温度65℃で24時間乾燥する。得られた生成物は、7.0°±0.2、7.3°±0.2、8.2°±0.2、8.7°±0.2、10.3°±0.2、11.1°±0.2、11.7°±0.2、12.4°±0.2、14.5°±0.2、16.3°±0.2、17.2°±0.2、18.0°±0.2、19.4°±0.2の角度2θの値においてピークを示す粉末X線ディフラクトグラムを特徴とするリファキシミンεである。
(経口投与によるイヌでの生物学的利用可能性)
20週齢で5.0〜7.5kgの8匹の純血種ビーグルメスイヌを、4匹ずつの2つのグループに分けた。
Tmax=Cmaxが達成される時間
AUC=線形台形公式により計算された濃度−時間曲線における面積
表1に報告された結果は、実際に吸収されないリファキシミンεに対し、いかにリファキシミンδが吸収されるか(40倍以上)を明確に示している。
Claims (16)
- 5.7°±0.2、6.7°±0.2、7.1°±0.2、8.0°±0.2、8.7°±0.2、10.4°±0.2、10.8°±0.2、11.3°±0.2、12.1°±0.2、17.0°±0.2、17.3°±0.2、17.5°±0.2、18.5°±0.2、18.8°±0.2、19.1°±0.2、21.0°±0.2、21.5°±0.2の回折角2θの値にパターンピークを示す粉末X線ディフラクトグラムを特徴とする、リファキシミンの多形結晶δ。
- 含水量が2.5%(w/w)〜6%(w/w)である請求項1記載の多形結晶δ。
- 含水量が3.0%(w/w)〜4.5%(w/w)である請求項1又は2記載のリファキシミンの多形結晶δ。
- 7.0°±0.2、7.3°±0.2、8.2°±0.2、8.7°±0.2、10.3°±0.2、11.1°±0.2、11.7°±0.2、12.4°±0.2、14.5°±0.2、16.3°±0.2、17.2°±0.2、18.0°±0.2、19.4°±0.2の回折角2θの値にパターンピークを示す粉末X線ディフラクトグラムを特徴とする、リファキシミンの多形結晶ε。
- 水とエチルアルコールとの1:1〜2:1の体積比の混合溶媒中、1モル当量のリファマイシンOを、過剰量の2−アミノ−4−メチルピリジンと、40℃〜60℃の温度で2〜8時間反応させること、その反応物を、室温で、水、エチルアルコールおよび濃塩酸の混合物中でアスコルビン酸溶液で処理すること、その反応物を濃塩酸によりpHを2.0にすること、懸濁液を濾過すること、得られた固体を前記反応で用いたものと同じ水/エチルアルコール混合溶媒で洗うこと、および、このように得られた固体粗リファキシミンを、含水量が2.5%(w/w)〜6.0%(w/w)になるまで乾燥することを特徴とする、請求項1記載のリファキシミン多形結晶δの製造方法。
- 1モル当量のリファマイシンOに対する2−アミノ−4−メチルピリジンの使用量が2.0〜3.5モル当量である請求項5記載の製造方法。
- 含水量が3.0%〜4.5%になるまで乾燥する請求項5又は6記載の製造方法。
- 減圧下で室温または高温で6〜24時間、請求項1記載のリファキシミン多形結晶δを乾燥することにより、リファキシミン多形結晶δを、7.0°±0.2、7.3°±0.2、8.2°±0.2、8.7°±0.2、10.3°±0.2、11.1°±0.2、11.7°±0.2、12.4°±0.2、14.5°±0.2、16.3°±0.2、17.2°±0.2、18.0°±0.2、19.4°±0.2の回折角2θの値にパターンピークを示す粉末X線ディフラクトグラムを有するリファキシミンの多形結晶εに転化させることを特徴とする、リファキシミン多形結晶εを製造する方法。
- 水とエチルアルコールとの1:1〜2:1の体積比の混合溶媒中、1モル当量のリファマイシンOを、過剰量の2−アミノ−4−メチルピリジンと、40℃〜60℃の温度で2〜8時間反応させ、
その反応物を、室温で、水、エチルアルコールおよび濃塩酸の混合物中でアスコルビン酸溶液で処理し、
その反応物を濃塩酸によりpHを2.0にし、
懸濁液を濾過し、
得られた固体を前記反応で用いたものと同じ水/エチルアルコール混合溶媒で洗い、
固体粗リファキシミンを含水量が2.5%(w/w)〜6.0%(w/w)になるまで乾燥する
ことにより得られる請求項1記載のリファキシミン多形結晶δ。 - 減圧下で室温または高温で6〜24時間、請求項1、2、3又は9記載のリファキシミン多形結晶δを乾燥して結晶形を転化させることにより得られる請求項4記載のリファキシミン多形結晶ε。
- 薬学的に許容可能な賦形剤と、請求項1、2、3もしくは9記載のリファキシミン多形結晶δ、又は請求項4もしくは10記載のリファキシミン多形結晶εとを含む医薬製剤。
- 固形製剤である請求項11記載の医薬製剤。
- 錠剤、硬質および軟質ゼラチンカプセル、糖衣丸剤、トローチ、オブラート、ペレット、又は密封包装中の粉末の形態である請求項11又は12記載の医薬製剤。
- 経口用である請求項11〜13のいずれかに記載の医薬製剤。
- 軟膏、ポマード、クリーム、ゲル又はローションの形態である請求項11記載の医薬製剤。
- 請求項1、2、3若しくは9記載のリファキシミン多形結晶δ、又は請求項4若しくは10記載のリファキシミン多形結晶εを含む局所用の医薬製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05004695.2 | 2005-03-03 | ||
EP05004695.2A EP1698630B1 (en) | 2005-03-03 | 2005-03-03 | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
PCT/EP2006/001755 WO2006094662A1 (en) | 2005-03-03 | 2006-02-27 | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013160684A Division JP2013216710A (ja) | 2005-03-03 | 2013-08-01 | リファキシミンの新規多形、その製造方法、及び医薬製剤中でのその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008531623A JP2008531623A (ja) | 2008-08-14 |
JP5737825B2 true JP5737825B2 (ja) | 2015-06-17 |
Family
ID=34934045
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007557398A Active JP5737825B2 (ja) | 2005-03-03 | 2006-02-27 | リファキシミンの新規多形、その製造方法、及び医薬製剤中でのその使用 |
JP2013160684A Withdrawn JP2013216710A (ja) | 2005-03-03 | 2013-08-01 | リファキシミンの新規多形、その製造方法、及び医薬製剤中でのその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013160684A Withdrawn JP2013216710A (ja) | 2005-03-03 | 2013-08-01 | リファキシミンの新規多形、その製造方法、及び医薬製剤中でのその使用 |
Country Status (28)
Country | Link |
---|---|
US (9) | US8193196B2 (ja) |
EP (1) | EP1698630B1 (ja) |
JP (2) | JP5737825B2 (ja) |
KR (1) | KR100885755B1 (ja) |
CN (1) | CN1900077B (ja) |
AU (1) | AU2006222312B8 (ja) |
BR (1) | BRPI0608073A8 (ja) |
CA (1) | CA2594789C (ja) |
DK (1) | DK1698630T3 (ja) |
ES (1) | ES2522895T3 (ja) |
HK (1) | HK1096396A1 (ja) |
HR (1) | HRP20070433B1 (ja) |
IL (1) | IL184694A0 (ja) |
MA (1) | MA29345B1 (ja) |
MD (1) | MD4081G2 (ja) |
ME (1) | ME00272B (ja) |
MX (1) | MX2007010742A (ja) |
NO (1) | NO342197B1 (ja) |
NZ (1) | NZ556737A (ja) |
PL (1) | PL1698630T3 (ja) |
PT (1) | PT1698630E (ja) |
RS (1) | RS54570B1 (ja) |
RU (1) | RU2397985C2 (ja) |
SI (1) | SI1698630T1 (ja) |
TN (1) | TNSN07292A1 (ja) |
UA (1) | UA89809C2 (ja) |
WO (1) | WO2006094662A1 (ja) |
ZA (1) | ZA200707397B (ja) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
ES2522895T3 (es) | 2005-03-03 | 2014-11-19 | Alfa Wassermann S.P.A. | Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales |
ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
KR101667534B1 (ko) * | 2006-09-22 | 2016-10-19 | 씨아이피엘에이 엘티디. | 리팍시민 |
ITMI20071241A1 (it) * | 2007-06-20 | 2008-12-21 | Solmag S P A | Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta |
US7709634B2 (en) | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
MY158257A (en) | 2008-02-25 | 2016-09-30 | Salix Pharmaceuticals Ltd | Forms of rifaximin and uses thereof |
US8486956B2 (en) * | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
AU2009219240B2 (en) | 2008-02-26 | 2014-10-16 | Salix Pharmaceuticals, Ltd. | Methods for treating bowel diseases |
US11779571B2 (en) | 2008-02-26 | 2023-10-10 | Salix Pharmaceuticals, Inc. | Methods for treating irritable bowel syndrome (IBS) |
US20090324736A1 (en) | 2008-05-07 | 2009-12-31 | Salix Pharmaceuticals, Ltd. | Methods of treating bowel diseases by administering a bowel cleanser and an antibiotic |
CN102164599B (zh) | 2008-09-26 | 2014-07-23 | Aska制药株式会社 | 预防和/或治疗功能性胃肠障碍的药剂 |
MX2011003548A (es) | 2008-10-02 | 2011-06-21 | Salix Pharmaceuticals Ltd | Metodos para tratar la encefalopatia hepatica. |
US20110035232A1 (en) * | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
US7928115B2 (en) * | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
JP5756020B2 (ja) | 2008-12-10 | 2015-07-29 | シプラ・リミテッド | リファキシミン複合体 |
KR20120062897A (ko) | 2009-09-13 | 2012-06-14 | 샐릭스 파마슈티컬스 리미티드 | 과민성 장 증후군(ibs)의 치료방법 |
RU2012126084A (ru) | 2009-11-23 | 2013-12-27 | Сипла Лимитед | Пенная композиция для местного применения |
WO2011080691A1 (en) | 2009-12-28 | 2011-07-07 | Silvio Massimo Lavagna | Method for the production of amorphous rifaximin |
CA2789929C (en) | 2010-02-18 | 2019-11-26 | Salix Pharmaceuticals, Ltd. | Methods for treating infection |
IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
CN101836959A (zh) * | 2010-05-20 | 2010-09-22 | 山东达因海洋生物制药股份有限公司 | 一种制备几乎无苦味利福昔明干混悬剂的方法 |
US8883795B2 (en) * | 2010-06-16 | 2014-11-11 | Apotex Pharmachem Inc. | Polymorphic forms of Rifaximin |
CA2804635C (en) | 2010-07-12 | 2019-09-10 | Salix Pharmaceuticals, Ltd. | Formulations of rifaximin and uses thereof |
WO2012035544A2 (en) | 2010-09-13 | 2012-03-22 | Sequent Scientific Ltd. | A novel polymorphic form of rifaximin and process for its preparation |
IT1403847B1 (it) | 2010-09-22 | 2013-11-08 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina e loro uso. |
AU2012214239B2 (en) | 2011-02-11 | 2016-06-30 | Salix Pharmaceuticals, Ltd. | Forms of Rifaximin and uses thereof |
WO2012150561A1 (en) | 2011-05-02 | 2012-11-08 | Ranbaxy Laboratories Limited | Rifaximin dimethylformamide solvate |
ITMI20110890A1 (it) * | 2011-05-19 | 2012-11-20 | A M S A Anonima Materie Sint & Affini S P A | Polimorfo di rifaximina e processo per la sua preparazione |
WO2013027227A1 (en) * | 2011-07-20 | 2013-02-28 | Ind-Swift Laboratories Limited | Novel polymorphic form i of rifaximin |
ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
WO2013067394A1 (en) | 2011-11-02 | 2013-05-10 | Salix Pharmaceuticals, Ltd | Methods for treating irritable bowel syndrome (ibs) and infections |
US9359374B2 (en) | 2012-06-13 | 2016-06-07 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
US9849090B2 (en) | 2012-12-12 | 2017-12-26 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of rifaximin |
US20160047819A1 (en) | 2013-03-15 | 2016-02-18 | Alfa Wassermann S.P.A. | Method for diagnosing vaginal infections |
US20160038468A1 (en) | 2013-03-15 | 2016-02-11 | Alfa Wassermann S.P.A. | Rifaximin for use in the treating of vaginal infections |
KR102190173B1 (ko) | 2013-04-12 | 2020-12-14 | 알파시그마 에스.피.에이. | Nsaid 투여 및 관련 조성물, 방법 및 시스템 |
US9018225B1 (en) | 2013-07-26 | 2015-04-28 | Novel Laboratories | Rifaximin crystalline forms and methods of preparation thereof |
US9736829B2 (en) * | 2013-10-14 | 2017-08-15 | Qualcomm Incorporated | Downlink control management in an unlicensed or shared spectrum |
EP2927235B1 (en) | 2014-03-31 | 2017-02-08 | Euticals S.P.A. | Polymorphic mixture of rifaximin and its use for the preparation of solid formulations |
CA2946101A1 (en) * | 2014-04-19 | 2015-10-22 | Granules India Limited | An improved process for the preparation of rifamycin derivatives |
JP6693946B2 (ja) | 2014-05-04 | 2020-05-13 | サリックス ファーマスーティカルズ,インコーポレーテッド | Ibs微生物叢及びその使用 |
KR102362719B1 (ko) | 2014-05-12 | 2022-02-14 | 알파시그마 에스.피.에이. | 리팍시민의 신규한 용매화 결정 형태, 생산물, 조성물 및 이의 용도 |
EP2982764A1 (en) | 2014-08-05 | 2016-02-10 | ALFA WASSERMANN S.p.A. | Identification of vaginal bacteria |
CA2992945A1 (en) | 2015-07-17 | 2017-01-26 | Memorial Sloan-Kettering Cancer Center | Combination therapy using pdk1 and pi3k inhibitors |
PL3373914T5 (pl) | 2016-03-24 | 2022-10-17 | Sandoz Ag | Trwała przy przechowywaniu kompozycja zawierająca rifaksyminę alfa |
US10576065B2 (en) | 2016-03-24 | 2020-03-03 | Sandoz Ag | Pharmaceutical composition containing rifaximin alpha and delta |
US9988398B2 (en) | 2016-06-07 | 2018-06-05 | Cadila Healthcare Limited | Crystalline form of rifaximin and process for its preparation |
ES2929768T3 (es) | 2016-09-30 | 2022-12-01 | Salix Pharmaceuticals Inc | Formas sólidas de dispersión de rifaximina |
AU2018211305B2 (en) | 2017-04-26 | 2019-07-25 | Sandoz Ag | Oral dosage form comprising rifaximin in form beta |
IT201700091912A1 (it) * | 2017-08-08 | 2019-02-08 | Biofer Spa | Nuove pirido-imidazo rifamicine |
CN110770244A (zh) | 2017-06-26 | 2020-02-07 | 倍尔福股份公司 | 吡啶并咪唑利福霉素衍生物的抗菌剂 |
CA3142214A1 (en) | 2019-06-03 | 2020-12-10 | Bausch Health Ireland Limited | Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders |
JP2022548788A (ja) | 2019-09-24 | 2022-11-21 | バウシュ ヘルス アイルランド リミテッド | リファキシミン液体製剤 |
WO2021191312A1 (en) | 2020-03-24 | 2021-09-30 | Bausch Health Ireland Limited | Methods of treating covid-19 with rifaximin |
AU2021298178A1 (en) | 2020-06-26 | 2023-02-02 | Bausch Health Ireland Limited | Targeted release rifaximin compositions |
US20230398102A1 (en) | 2020-10-29 | 2023-12-14 | Bausch Health Ireland Limited | Rifaximin liquid formulations for use inthe treatment of sickle cell disease |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH547854A (de) | 1969-05-30 | 1974-04-11 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von antibiotika. |
CH571064A5 (en) | 1973-03-01 | 1975-12-31 | Archifar Ind Chim Trentino | Recovery of rieamycin from broths - by oxidn to an insol form |
US4267274A (en) | 1973-04-26 | 1981-05-12 | Gruppo Lepetit S.P.A. | Streptomyces mediterranei mutant capable of production of rifamycin B |
GB1470426A (en) | 1974-08-30 | 1977-04-14 | Lepetit Spa | Rifamycins |
IT1154655B (it) * | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
IT1199374B (it) | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
CA1215976A (en) | 1984-05-15 | 1986-12-30 | Vincenzo Cannata | New process for the synthesis of imidazo rifamycins |
IT1199413B (it) | 1984-09-26 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
US5356625A (en) | 1986-08-28 | 1994-10-18 | Enzacor Properties Limited | Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals |
GB8816620D0 (en) * | 1988-07-13 | 1988-08-17 | Lepetit Spa | Rifapentine hydrohalides |
KR0170000B1 (ko) * | 1990-06-29 | 1999-02-01 | 레나토 스가르비 | 순수한 결정 형태의 리파펜틴 |
IT1253711B (it) | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali |
IT1264494B1 (it) | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
US6271001B1 (en) | 1995-03-23 | 2001-08-07 | Bio Polymers Pty. Ltd. | Cultured plant cell gums for food, pharmaceutical, cosmetic and industrial applications |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
EP0935417B1 (en) | 1996-10-16 | 2009-05-06 | Napo Pharmaceuticals, Inc. | Enteric formulations of proanthocyanidin polymer antidiarrheal compositions |
IT1290679B1 (it) | 1997-02-14 | 1998-12-10 | Alfa Wassermann Spa | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
US20030157174A1 (en) | 2000-03-23 | 2003-08-21 | Takayuki Tsukuda | Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component |
US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
WO2002036542A1 (en) * | 2000-10-31 | 2002-05-10 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of venlafaxine hydrochloride |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
CN1226037C (zh) | 2001-05-03 | 2005-11-09 | 法米基股份公司 | 硫糖铝在制备治疗宫颈糜烂药物上的用途 |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
WO2003101460A1 (fr) | 2002-06-03 | 2003-12-11 | Cac Corporation | Preparations a usage externe pour le traitement de la dermatite |
CZ13908U1 (cs) | 2003-10-08 | 2004-01-05 | Cpn Spol. S R.O. | Kosmetický přípravek s vysokomolekulární antioxidační složkou |
US20080262024A1 (en) | 2003-11-07 | 2008-10-23 | Giuseppe Claudio Viscomi | Rifaximin compositions and method of use |
US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
US7923553B2 (en) | 2003-11-07 | 2011-04-12 | Alfa Wassermann, S.P.A. | Processes for the production of polymorphic forms of rifaximin |
US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
US20050196418A1 (en) | 2004-03-04 | 2005-09-08 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
US20050256118A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
EP1778195A2 (en) | 2004-07-16 | 2007-05-02 | Cipla Limited | Anti-histaminic composition |
US20060210492A1 (en) | 2005-03-02 | 2006-09-21 | Kodsi Robert E | Use of rifaximin for treatment and prevention of periodontal conditions |
US8003118B2 (en) | 2005-03-02 | 2011-08-23 | Kodsi Robert E | Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis |
US20060210483A1 (en) | 2005-03-02 | 2006-09-21 | Kodsi Robert E | Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections |
ES2522895T3 (es) | 2005-03-03 | 2014-11-19 | Alfa Wassermann S.P.A. | Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales |
ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
ITBO20050388A1 (it) | 2005-06-06 | 2006-12-07 | Alfa Wassermann Spa | Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche |
ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
KR101667534B1 (ko) | 2006-09-22 | 2016-10-19 | 씨아이피엘에이 엘티디. | 리팍시민 |
ITMI20071241A1 (it) | 2007-06-20 | 2008-12-21 | Solmag S P A | Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta |
WO2009008006A2 (en) | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions for gastrointestinal drug delivery |
EP2837378A1 (en) | 2007-07-06 | 2015-02-18 | Lupin Limited | Pharmaceutical compositions of rifaximin |
WO2009008005A1 (en) | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions of rifaximin |
JP2010259452A (ja) * | 2007-08-21 | 2010-11-18 | Konica Minolta Medical & Graphic Inc | 画像診断支援装置及び画像診断支援方法 |
US7709634B2 (en) | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
JP2011500552A (ja) | 2007-10-10 | 2011-01-06 | ルピン・リミテッド | 胃腸障害を処置するための医薬用組み合わせおよび組成物 |
US8486956B2 (en) | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
MY158257A (en) | 2008-02-25 | 2016-09-30 | Salix Pharmaceuticals Ltd | Forms of rifaximin and uses thereof |
AU2009219240B2 (en) | 2008-02-26 | 2014-10-16 | Salix Pharmaceuticals, Ltd. | Methods for treating bowel diseases |
US20090324736A1 (en) | 2008-05-07 | 2009-12-31 | Salix Pharmaceuticals, Ltd. | Methods of treating bowel diseases by administering a bowel cleanser and an antibiotic |
US7928115B2 (en) | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
US20100317681A1 (en) | 2009-06-15 | 2010-12-16 | Salix Pharmaceuticals, Ltd. | Modulation of systemic exposure to rifaximin |
MX2011003548A (es) | 2008-10-02 | 2011-06-21 | Salix Pharmaceuticals Ltd | Metodos para tratar la encefalopatia hepatica. |
US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
WO2010044093A1 (en) | 2008-10-16 | 2010-04-22 | Strides Arcolab Limited | Formulations containing rifaximin |
JP5756020B2 (ja) | 2008-12-10 | 2015-07-29 | シプラ・リミテッド | リファキシミン複合体 |
JP5276505B2 (ja) * | 2009-04-06 | 2013-08-28 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
IT1397617B1 (it) | 2009-04-20 | 2013-01-18 | Alfa Wassermann Spa | Nuovi derivati della rifamicina |
RU2571268C2 (ru) | 2009-06-15 | 2015-12-20 | Саликс Фармасьютикалз, Лтд. | Модуляция системного воздействия рифаксимина |
KR20120062897A (ko) | 2009-09-13 | 2012-06-14 | 샐릭스 파마슈티컬스 리미티드 | 과민성 장 증후군(ibs)의 치료방법 |
CA2778181A1 (en) | 2009-10-26 | 2011-05-05 | Thomas Julius Borody | Therapy for enteric infections |
EP2493456B1 (en) | 2009-10-27 | 2018-11-21 | Lupin Limited | Solid dispersion of rifaximin |
WO2011061748A1 (en) | 2009-11-19 | 2011-05-26 | Strides Arcolab Limited | Rifaximin premix |
KR20120099731A (ko) | 2009-11-23 | 2012-09-11 | 시플라 리미티드 | 국소용 폼 조성물 |
RU2012126084A (ru) | 2009-11-23 | 2013-12-27 | Сипла Лимитед | Пенная композиция для местного применения |
WO2011080691A1 (en) | 2009-12-28 | 2011-07-07 | Silvio Massimo Lavagna | Method for the production of amorphous rifaximin |
CN101773465B (zh) | 2010-01-19 | 2012-11-07 | 南京泛太化工医药研究所 | 以氨基酸为稳定剂的聚合物胶束载药系统 |
CA2789929C (en) | 2010-02-18 | 2019-11-26 | Salix Pharmaceuticals, Ltd. | Methods for treating infection |
IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
US9211258B2 (en) | 2010-03-10 | 2015-12-15 | Lupin Limited | Rifaximin ready-to-use suspension |
TR201810936T4 (tr) | 2010-04-23 | 2018-08-27 | Industrial Chemicals Group Ltd | Deterjan bileşimi. |
KR20130086338A (ko) | 2010-06-03 | 2013-08-01 | 샐릭스 파마슈티컬스 리미티드 | 리팍시민의 신규한 형태들 및 이들의 용도 |
US8883795B2 (en) | 2010-06-16 | 2014-11-11 | Apotex Pharmachem Inc. | Polymorphic forms of Rifaximin |
CA2804635C (en) | 2010-07-12 | 2019-09-10 | Salix Pharmaceuticals, Ltd. | Formulations of rifaximin and uses thereof |
WO2012035544A2 (en) | 2010-09-13 | 2012-03-22 | Sequent Scientific Ltd. | A novel polymorphic form of rifaximin and process for its preparation |
EP2616044A1 (en) | 2010-09-13 | 2013-07-24 | Cilpa Limited | Pharmaceutical composition |
IT1403847B1 (it) | 2010-09-22 | 2013-11-08 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina e loro uso. |
WO2012060675A1 (es) | 2010-11-05 | 2012-05-10 | Interquim, S.A. De C.V. | Proceso para la preparación de rifaximina amorfa |
WO2012076832A1 (en) | 2010-12-09 | 2012-06-14 | Cipla Limited | Suppositories comprising rifaximin |
AU2012214239B2 (en) | 2011-02-11 | 2016-06-30 | Salix Pharmaceuticals, Ltd. | Forms of Rifaximin and uses thereof |
WO2012150561A1 (en) | 2011-05-02 | 2012-11-08 | Ranbaxy Laboratories Limited | Rifaximin dimethylformamide solvate |
ITMI20110890A1 (it) | 2011-05-19 | 2012-11-20 | A M S A Anonima Materie Sint & Affini S P A | Polimorfo di rifaximina e processo per la sua preparazione |
WO2012155981A1 (en) | 2011-05-19 | 2012-11-22 | Friulchem Spa | New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby |
ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
WO2013067394A1 (en) | 2011-11-02 | 2013-05-10 | Salix Pharmaceuticals, Ltd | Methods for treating irritable bowel syndrome (ibs) and infections |
WO2013112809A2 (en) | 2012-01-25 | 2013-08-01 | Salix Pharmaceuticals, Ltd | Rifaximin derivative and uses thereof |
JP2013184902A (ja) | 2012-03-06 | 2013-09-19 | Aska Pharmaceutical Co Ltd | リファキシミン含有結晶 |
US9359374B2 (en) | 2012-06-13 | 2016-06-07 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
US9849090B2 (en) | 2012-12-12 | 2017-12-26 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of rifaximin |
KR102190173B1 (ko) | 2013-04-12 | 2020-12-14 | 알파시그마 에스.피.에이. | Nsaid 투여 및 관련 조성물, 방법 및 시스템 |
JP2016526032A (ja) | 2013-05-17 | 2016-09-01 | サリックス ファーマスーティカルズ,インコーポレーテッド | ポジション(position)放射断層撮影(pet)スキャンでリファキシミンを使用する方法 |
US9018225B1 (en) | 2013-07-26 | 2015-04-28 | Novel Laboratories | Rifaximin crystalline forms and methods of preparation thereof |
ITMI20131307A1 (it) | 2013-08-02 | 2015-02-02 | A M S A Anonima Materie Sint & Affini S P A | Processo per la preparazione di refaximina k |
EP2927235B1 (en) | 2014-03-31 | 2017-02-08 | Euticals S.P.A. | Polymorphic mixture of rifaximin and its use for the preparation of solid formulations |
CA2946101A1 (en) | 2014-04-19 | 2015-10-22 | Granules India Limited | An improved process for the preparation of rifamycin derivatives |
KR102362719B1 (ko) | 2014-05-12 | 2022-02-14 | 알파시그마 에스.피.에이. | 리팍시민의 신규한 용매화 결정 형태, 생산물, 조성물 및 이의 용도 |
WO2016063289A2 (en) | 2014-10-22 | 2016-04-28 | Strides Arcolab Limited | Pharmaceutical tablet compositions comprising rifaximin |
WO2017021975A1 (en) | 2015-08-06 | 2017-02-09 | Msn Laboratories Private Limited | Process for the preparation of crystalline forms of rifaximin |
PL3373914T5 (pl) | 2016-03-24 | 2022-10-17 | Sandoz Ag | Trwała przy przechowywaniu kompozycja zawierająca rifaksyminę alfa |
US10576065B2 (en) | 2016-03-24 | 2020-03-03 | Sandoz Ag | Pharmaceutical composition containing rifaximin alpha and delta |
US9988398B2 (en) | 2016-06-07 | 2018-06-05 | Cadila Healthcare Limited | Crystalline form of rifaximin and process for its preparation |
WO2018158646A1 (en) | 2017-03-02 | 2018-09-07 | Granules India Limited | Rifaximin crystalline form |
WO2018178777A1 (en) | 2017-03-31 | 2018-10-04 | Granules India Limited | Process for the preparation of rifaximin crystalline form |
AU2018211305B2 (en) | 2017-04-26 | 2019-07-25 | Sandoz Ag | Oral dosage form comprising rifaximin in form beta |
CN110770244A (zh) | 2017-06-26 | 2020-02-07 | 倍尔福股份公司 | 吡啶并咪唑利福霉素衍生物的抗菌剂 |
-
2005
- 2005-03-03 ES ES05004695.2T patent/ES2522895T3/es active Active
- 2005-03-03 DK DK05004695.2T patent/DK1698630T3/da active
- 2005-03-03 PL PL05004695T patent/PL1698630T3/pl unknown
- 2005-03-03 EP EP05004695.2A patent/EP1698630B1/en not_active Revoked
- 2005-03-03 PT PT50046952T patent/PT1698630E/pt unknown
- 2005-03-03 SI SI200531897T patent/SI1698630T1/sl unknown
- 2005-07-20 CN CN2005100851226A patent/CN1900077B/zh active Active
- 2005-07-28 KR KR1020050068982A patent/KR100885755B1/ko active IP Right Grant
-
2006
- 2006-02-27 ME MEP-2008-344A patent/ME00272B/me unknown
- 2006-02-27 AU AU2006222312A patent/AU2006222312B8/en active Active
- 2006-02-27 CA CA2594789A patent/CA2594789C/en active Active
- 2006-02-27 NZ NZ556737A patent/NZ556737A/en unknown
- 2006-02-27 RU RU2007136430/04A patent/RU2397985C2/ru active
- 2006-02-27 MX MX2007010742A patent/MX2007010742A/es active IP Right Grant
- 2006-02-27 RS RS20070364A patent/RS54570B1/en unknown
- 2006-02-27 BR BRPI0608073A patent/BRPI0608073A8/pt not_active Application Discontinuation
- 2006-02-27 JP JP2007557398A patent/JP5737825B2/ja active Active
- 2006-02-27 ZA ZA200707397A patent/ZA200707397B/xx unknown
- 2006-02-27 UA UAA200708880A patent/UA89809C2/uk unknown
- 2006-02-27 WO PCT/EP2006/001755 patent/WO2006094662A1/en not_active Application Discontinuation
- 2006-02-27 US US11/658,702 patent/US8193196B2/en active Active
- 2006-02-27 MD MDA20070265A patent/MD4081G2/ro active IP Right Grant
-
2007
- 2007-04-03 HK HK07103565.2A patent/HK1096396A1/xx unknown
- 2007-07-18 IL IL184694A patent/IL184694A0/en active IP Right Grant
- 2007-07-24 TN TNP2007000292A patent/TNSN07292A1/en unknown
- 2007-09-20 HR HRP20070433AA patent/HRP20070433B1/hr active IP Right Grant
- 2007-09-26 MA MA30245A patent/MA29345B1/fr unknown
- 2007-10-03 NO NO20074988A patent/NO342197B1/no unknown
-
2012
- 2012-06-04 US US13/488,345 patent/US8518949B2/en active Active
-
2013
- 2013-07-25 US US13/950,642 patent/US8741904B2/en active Active
- 2013-08-01 JP JP2013160684A patent/JP2013216710A/ja not_active Withdrawn
-
2014
- 2014-04-25 US US14/262,612 patent/US9271968B2/en active Active
-
2016
- 2016-01-12 US US14/994,079 patent/US20160362419A1/en not_active Abandoned
-
2017
- 2017-11-13 US US15/811,536 patent/US20180291032A1/en not_active Abandoned
-
2019
- 2019-03-04 US US16/291,900 patent/US10703763B2/en active Active
-
2020
- 2020-05-19 US US16/878,511 patent/US20200277301A1/en not_active Abandoned
-
2021
- 2021-12-28 US US17/563,579 patent/US20220119403A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5737825B2 (ja) | リファキシミンの新規多形、その製造方法、及び医薬製剤中でのその使用 | |
US20200339599A1 (en) | Polymorphic forms alpha, beta and gamma of rifaximin | |
JP5635376B2 (ja) | リファキシミンの多形体、それらの製造方法および医薬製剤におけるそれらの使用 | |
US20120214989A1 (en) | Processes for the production of polymorphic forms of rifaximin | |
US20120035202A1 (en) | Rifaximin compositions and method of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081119 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100910 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101013 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120417 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120424 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120517 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120524 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120615 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120615 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130801 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130808 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20131101 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140131 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150317 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150421 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5737825 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |